If you’re taking Aimovig or Qulipta to prevent migraines, it’s good to know how they work and if they can interact with each other. Both are part of a group called CGRP inhibitors. Aimovig is given as an injection and blocks the CGRP receptor in your body.
Qulipta is a pill that also targets CGRP to stop migraines. So far, there’s no direct problem when taking both together, but it’s still important to talk to your doctor before using them at the same time because of potential risks.
Aimovig (erenumab) and Qulipta (atogepant) are both medications used for the preventive treatment of migraines, but they belong to different classes of drugs. Aimovig is a monoclonal antibody administered via a monthly subcutaneous injection, while Qulipta is an oral medication taken daily. Both medications target the calcitonin gene-related peptide (CGRP) pathway, which is believed to play a critical role in migraine attacks.
Clinical studies have shown that both Aimovig and Qulipta are effective in reducing the frequency of migraine days.
Aimovig has been shown to reduce the number of monthly migraine days by three to four days, with some patients experiencing at least a 50% reduction in migraine days. Similarly, Qulipta has demonstrated efficacy in reducing the average number of monthly migraine days compared to placebo.
When it comes to combining these two medications, there are no known interactions between Aimovig and Qulipta. However, it is important to note that both medications belong to the CGRP inhibitor class, and using them together may increase the risk of side effects associated with this class.
The most common side effects of Aimovig include injection site reactions, constipation, and muscle spasms.
On the other hand, Qulipta’s most common side effects are nausea, constipation, and fatigue. Both medications have been shown to have a favorable safety profile, but it is essential to consult with a healthcare provider before combining them to ensure that the benefits outweigh the risks.
In summary, while there are no known interactions between Aimovig and Qulipta, combining these medications may increase the risk of side effects associated with CGRP inhibitors. Patients should consult their healthcare provider to discuss the potential benefits and risks of using these medications together.
Aimovig (erenumab) and Qulipta (atogepant) are both medications used to prevent migraines, but they belong to different classes of drugs. Aimovig is an injection that blocks the CGRP receptor in the body, while Qulipta is a pill that targets CGRP to stop migraines.
Clinical studies have shown that both medications are effective in reducing the frequency of migraine days. However, when taken together, there may be an increased risk of side effects associated with CGRP inhibitors.
The most common side effects of Aimovig include injection site reactions, constipation, and muscle spasms, while Qulipta’s most common side effects are nausea, constipation, and fatigue. Despite this, both medications have a favorable safety profile.
It is essential to consult with a healthcare provider before combining these medications to ensure that the benefits outweigh the risks. While there are no known interactions between Aimovig and Qulipta, it’s still crucial to discuss potential risks and benefits with your doctor before making any changes to your medication regimen.
In conclusion, if you’re considering taking both Aimovig and Qulipta together, consult with your healthcare provider to weigh the pros and cons. They can help determine whether combining these medications is safe and effective for you.